Skip to main content

Linguamatics NLP COVID-19 Evidence Hub

  1. Overview
  2. Features & Benefits
  3. COVID-19 Global Publications Dashboard

Rapid, effective scientific evidence generation from text for scientific and clinical decision making.


In the rapidly evolving fight against COVID-19, pharmaceutical and healthcare organizations, governments, and the broader scientific communities around the world are working to assess the impact of the virus, and quickly develop fast, accurate solutions.

To get there, researchers  and teams must have access to the best, and most up to date, evidence from a broad range of data sources including scientific literature, clinical trials and other textual sources.

Linguamatics’ natural language processing (NLP) technology enables fast, systematic, comprehensive insight generation from unstructured text. Sources can include scientific literature, clinical trial records, preprints, internal sources, medical records, social media and news reports. Capturing the key information from these many sources, and synthesizing it into one Evidence Hub, deepens understanding for our users, which will in turn accelerate outcomes.

Key features & benefits of the COVID-19 Evidence Hub

The Linguamatics NLP COVID-19 Evidence Hub integrates information from two focused COVID-19 related document sets - the COVID-19 Open Research Dataset (CORD19) compiled by the Allen Institute for AI and Elsevier’s COVID-19 full text papers - with MEDLINE®,, PubMed Central, and FDA Drug labels (from Linguamatics Content Cloud).

The Evidence Hub comprises a deep-dive search portal that enables users to build their own NLP-powered searches or use the library of queries provided. In addition, dashboards for data visualization and data drill-down are available, with links to the evidence contained within the underlying document sets.

Initially, there are three main evidence pillars that are enabled by access to integrated intelligence through the COVID-19 Evidence Hub:

  1. Prioritizing a known list of potential drugs
  2. De novo search for potential candidates
  3. Market insights that feed into repurposing and prioritization

Bringing together these evidence pillars will enable users to tackle short, medium and longer-term questions to confront the COVID-19 pandemic, such as:

  • Short-term
    What are the best potential drugs or drug combinations for repurposing efforts, or to treat critically ill patients? How can we find new candidates, and prioritise (with data on efficacy, safety, mechanism of action, and more)? How do I find recent trials, the most up-to-date research, the key opinion leaders and researchers in this field?
  • Medium-term
    What’s known about SARS-CoV-2 to enable vaccine development? Who in the population is most at-risk for severe disease? What are the key co-morbidities and are there therapeutics that can prevent COVID-19 impacting these populations?
  • Long-term
    How will my patient population respond to current drugs, after COVID-19 infection? What additional care pathways are needed? What potential new chronic conditions will be seen in patients who have recovered from COVID-19 and how can we treat these?

Linguamatics COVID-19 Global Publications Dashboard

Linguamatics has made a high-level trial and publication tracking dashboard freely available at (see below). This global view tracks existing research and clinical efforts: blue circles represent the location of the first author’s affiliation from MEDLINE® abstracts; and orange circles represent all of the study locations from
The map shows global locations of clinical trial studies (orange) and scientific papers (blue; first author). Linguamatics NLP is used to extract COVID-19 relevant abstracts and trial locations from MEDLINE® and to provide a global view that tracks up-to-date research efforts. Available at:

Covid-19 Publications dashboard

We’re ready to partner with you to help reduce the impact of COVID-19.

Download the datasheet or request a demo below.

We’re ready to partner with you to help reduce the impact of COVID-19

Ready to get started?

Request a Demo

Questions? Ask our experts